help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moretti, C.
Right arrow Articles by Catt, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moretti, C.
Right arrow Articles by Catt, K. J.

Endocrinology, Vol 127, 2117-2126, Copyright © 1990 by Endocrine Society


ARTICLES

Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation

C Moretti, A Bagnato, N Solan, G Frajese and KJ Catt
Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD 20892.

GRF promotes follicular maturation and ovulation when administered with FSH in the treatment of infertility. Such actions could be mediated by stimulation of GH secretion and insulin-like growth factor I production, but the known actions of the structurally related hormone, vasoactive intestinal peptide (VIP), on granulosa cell function suggested that GRF may also act directly on the ovary to stimulate follicular development. Radioligand binding and activation studies, performed in granulosa cells from immature estrogen-treated rats, revealed a common receptor for VIP and rat (r) GRF in the ovary. Specific binding of [125I]VIP to granulosa cells was saturable and dependent on time and temperature. The relative potencies of VIP- related peptides for inhibition of radioligand binding were: VIP greater than rGRF greater than peptide histidine isoleucinamide greater than [His1,Nle27] human GRF(1-32)NH2 greater than secretin. In binding studies with the potent GRF agonist, [125I] [His1,Nle27]GRF(1-32)NH2, relative potencies were: rGRF(1-43)OH greater than [His1,Nle27]human GRF(1-32)NH2 greater than VIP greater than peptide histidine isoleucinamide greater than secretin. Glucagon and gastric inhibitory peptide, other peptides of the glucagon superfamily, and unrelated peptides including CRF and beta-endorphin, did not inhibit binding of either radioligand to ovarian receptors. In cultured granulosa cells, rGRF and VIP stimulated cAMP formation, consistent with coupling of their receptors to the adenylate cyclase system, and potentiated FSH- induced cAMP production. Both peptides also amplified FSH-induced progesterone biosynthesis, aromatase activity, and LH receptor formation. These observations demonstrate that rGRF is a potent cAMP- mediated agonist in the rat ovary and acts on a common VIP/GRF receptor in maturing granulosa cells. It is likely that the potentiating effect of administered GRF on gonadotropin-stimulated follicular development in vivo is in part mediated by direct actions of the peptide on the VIP/GRF receptor. Also, since GRF is present in the gonads, it is possible that the locally-produced peptide promotes follicular maturation by paracrine modulation of the stimulatory action of FSH on granulosa cell function.


This article has been cited by other articles:


Home page
EndocrinologyHome page
Y. Kobayashi, F. Jimenez-Krassel, Q. Li, J. Yao, R. Huang, J. J. Ireland, P. M. Coussens, and G. W. Smith
Evidence that Cocaine- and Amphetamine-Regulated Transcript Is a Novel Intraovarian Regulator of Follicular Atresia
Endocrinology, November 1, 2004; 145(11): 5373 - 5383.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. M. Sherwood, S. L. Krueckl, and J. E. McRory
The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily
Endocr. Rev., December 1, 2000; 21(6): 619 - 670.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
Z. Kahán, J. M. Arencibia, V. J. Csernus, K. Groot, R. D. Kineman, W. R. Robinson, and A. V. Schally
Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian Cancers
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 582 - 589.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
S. Petersenn, A. C. Rasch, M. Heyens, and H. M. Schulte
Structure and Regulation of the Human Growth Hormone-Releasing Hormone Receptor Gene
Mol. Endocrinol., February 1, 1998; 12(2): 233 - 247.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Schwarzler, G. Untergasser, M. Hermann, S. Dirnhofer, B. Abendstein, S. Madersbacher, and P. Berger
Selective Growth Hormone/Placental Lactogen Gene Transcription and Hormone Production in Pre- and Postmenopausal Human Ovaries
J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3337 - 3341.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society